| Expression pattern: |
DN |
| Associated gene: |
ACSL6, AGO2 |
| Associated microRNA: |
miR-4298 |
| Biological function: |
inhibits proliferation; inhibits migration; inhibits invasion; promotes ferroptosis; suppresses tumor growth and metastasis |
| Molecular mechanism: |
ceRNA/miRNA sponge mechanism: circBNC2 sponges miR-4298 to upregulate ACSL6, which mediates circBNC2-induced ferroptosis |
| Biological pathway or process: |
ferroptosis (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Transwell Assay; Wound Healing Assay; Cell Cycle Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Survival Analysis |
| Clinical significance: |
Low circBNC2 expression was associated with tumor stage and Gleason grade; circBNC2 has the potential to be a biomarker for the diagnosis and prognosis of PCa |
| Description: |
circBNC2 (hsa_circ_0008732), derived from BNC2, is downregulated in prostate cancer tissues and cell lines. It suppresses tumor cell proliferation, migration and invasion and promotes ferroptosis by sponging miR-4298 to release ACSL6, and its low expression correlates with more advanced clinicopathological features. |
| Confidence score: |
0.8685 |